Publication: The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study: Difference between revisions
No edit summary |
(No difference)
|
Latest revision as of 11:15, 22 June 2024
| Reference | |
|---|---|
| Title | The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study |
| Topic | Vitamin B6 |
| Author | Ota, M, Tatsumi, K, Suwa, H, Watanabe, J, Watanabe, K, Osada, S, Tanaka, K, Shoichi, F, Ichikawa, Y, Kunisaki, C, Endo, I |
| Year | 2014 |
| Journal | Hepato-Gastroenterology |
| DOI | http://www.ncbi.nlm.nih.gov/pubmed/26158157 |
Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.
| Background/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine.
Methodology: Colorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended. Results: Sixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HES developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS was not different between the two groups. Conclusions: Pyridoxine is not effective in prevention of capecitabine-associated HFS. |
This publication is referenced in the following studies: